drugset / Trial / NCT00660829

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

NCT00660829

Phase 3 Completed 536 enrolled Meda Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The Purpose of this study is to determine if one allergy medication (0.15% azelastine hydrochloride) is more effective than Placebo alone.

Timeline

Start
2007-12
Primary completion
2008-02
Completion
2008-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Azelastine Small molecule 0.15 % Intranasal
Comparator Azelastine Small molecule 822 ug Intranasal